Debt-to-Equity Ratio

Abbott Laboratories' debt-to-equity ratio of 0.65x means the company uses $0.65 of debt for every $1 of shareholder equity, indicating a moderate reliance on borrowed funds relative to its own capital.

This ratio is above the healthcare sector median of 0.47x, placing Abbott in the 61st percentile among its peers, suggesting it carries more leverage than most companies in its industry. The metric has been perfectly stable over the past eight quarters, with year-over-year and quarter-over-quarter changes both at +0.0%, showing no movement in either direction. The combination of a debt-to-equity level slightly above the sector median with a flat trend implies a consistent, moderate financial risk profile—neither increasing nor decreasing pressure on the company's balance sheet. This stable, above-median leverage does not signal a concerning shift in risk, but it also offers no improving debt outlook. The neutral overall verdict on Abbott is supported by this metric, as the debt level is manageable but unremarkable versus peers, leaving the stock in a balanced risk-reward position.

Frequently Asked Questions

Closest Sector Peers